Amantadine hydrochloride treatment in heredodegenerative ataxias: A double blind study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 61, Issue 3, 1996, Pages 259-264

  Botez, M I ^a,b   Botez Marquard, Thérèse ^a   Elie, Robert ^b   Pedraza, Olga Lucia ^a   Goyette, Kristine ^a   Lalonde, Robert ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Amantadine hydrochloride; Friedreich's ataxia; Movement time; Olivopontocerebellar atrophy; Reaction time

Indexed keywords

AMANTADINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ANOREXIA; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; FEMALE; FRIEDREICH ATAXIA; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NIGHTMARE; OLIVOPONTOCEREBELLAR ATROPHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; TIME; TREATMENT OUTCOME;

EID: 0029814798     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.61.3.259     Document Type: Article

References (54)

1. Botez T, Botez MI, Parent C, Courchesne Y. Etude préliminaire évaluant l'effet à court terme de l'amantadine et du L-tryptophane associé au carbidopa dans le traitement des ataxies spinocérébelleuses. Méd Sci 1988; 2(suppl 1):46A.
2. Botez MI, Young SN, Botez T, Courchesne Y. Treatment of Friedreich's ataxia with amantadine letter. Neurology 1989;39:749-50.
3. Botez MI, Young SN, Botez T, Pedraza OL. Treatment of heredo-degenerative ataxias with amantadine hydrochloride. Can J Neurol Sci 1991;18:307-11.
4. Petersen PL, Saad J, Nigro MA. The treatment of Friedreich's ataxia with amantadine hydrochloride. Neurology 1988;38:1478-80.
5. Noica D, Draganesco S. Sur un symptôme caractéristique d'une lésion des noyaux centraux moteurs: la rigidité musculaire latente. Rev Neurol 1935;63:75-9.
6. Botez MI, Léveillé J, Lambert R, Botez Th. Single photon emission computed tomography (SPEGT) in cerebellar disease: cerebello-cerebral diaschisis. Eur Neurol 1991;31: 405-21.
7. Smedley hand dynamometer. Manual. Chicago: Stoelting Company, 1972:2. (Catalog number 19117.)
8. Benton AL, Blackburn HL. Practice effects in reaction time tasks in brain-injured patients. Journal of Abnormal Social Psychology 1957;54:109-13.
9. Ladurner G, Tschinkel M, Klebb H. Reaction time in cerebrovascular disease. Arch Gerontol Geriat 1985;4:373-9.
10. Baker SJ, Maurissen JP, Chrzan GJ. Simple reaction time and movement time in human volunteers. Percept Mot Skills 1986;63:767-74.
11. Botez MI, Gravel J, Attig E, Vézina JL. Reversible chronic cerebellar ataxia after phenytoin intoxication: possible role of the cerebellum in cognitive thought. Neurology 1985;35:1152-7.
12. Botez MI, Botez-Marquard T, Elie R, Attig E. Role of the cerebellum in complex human behavior. Ital J Neurol Sci 1989;10:291-300.
13. Botez MI. Cerebellum. In: Ramachandran VS, ed. Encyclopedia of human behavior. San Diego: Academic Press 1994;1:549-60.
14. Birren JE, Woods AM, Williams MV. Behavioral slowing with age: causes, organization, and consequences. In: Poon LW, ed. Aging in the 1980s: psychological issues. Washington, DC: American Psychological Association 1980:293-308.
15. Vernon PA. Speed of information processing and general intelligence. Intelligence 1983;7:53-70.
16. Jensen AR. Spearman's g: links between psychometrics and biology. Ann NY Acad Sci 1993;702:103-29.
17. Spirduso WW, MacRae HH, MacRae PG, Prewitt J, Osborne L. Exercise effects on age motor function. Ann NY Acad Sci 1988;515:363-75.
18. Hamsher KS, Benton AL. The reliability of reaction time determinations. Cortex 1977;3:305-10.
19. Botez MI, Attig E, Vézina JL. Cerebellar atrophy in epileptic patients. Can J Neurol Sci 1988;15:299-303.
20. Harding AE. The inherited ataxias. In: Di Donato S, ed. Advances in neurology. New York: Raven Press, 1988;48: 37-45.
21. Lopes-Cendes I, Andermann E, Attig E, et al. Confirmation of the SCA-2 locus as an alternative locus for dominantly inherited spinocerebellar ataxias and refinement of the candidate region. Am J Hum Genet 1994;54:774-81.
22. Shut JW, Haymaker W. Hereditary ataxia; pathological study of five cases of common ancestry. J Neuropathol Clin Neurol 1951;1:183-213.
23. Wadia NH, Swammi RK. A new form of heredofamilial spinocerebellar degeneration with slow eye movements. Brain 1971;94:359-74.
24. Huang YP, Plaitakis A. Morphological changes of olivopontocerebellar atrophy in computed tomography and comments on its pathogenesis. In: Duvoisin RC, Plaitakis A, eds. Advances in neurology. New York: Raven Press, 1984;41:39-86.
25. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: a new clinical profile for traumatic brain injury. Clin Pharmacol 1989;12:258-70.
26. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine. Pharmacopychiatry 1988;21:144-6.
27. Horiguchi J, Imami Y, Shoda T. Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 1990; 13:84-8.
28. Flaherty JA, Bellur SN. Mental side-effects of amantadine therapy: its spectrum and characteristics in a normal population. J Clin Psychiat 1981;42:9.
29. Monto SA, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. JAMA 1979;241: 1003-6.
30. Panagopoulos NT, Papadopoulos GC, Matsokis NA. Dopaminergic innervation and binding in the rat cerebellum. Neurosci Lett 1991;130:208-12.
31. Efthimiopoulos S, Giompres P, Valcana T. Kinetics of dopamine and noradrenaline transports in synaptosomes from cerebellum, striatum and frontal cortex of normal and reeler mice. J Neurosci Res 1991;29:510-9.
32. Polinsky RJ, Brown RT, Bums RS, Harvey-White J, Kopin IJ. Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomic failure. J Neurol Neurosurg Psychiatry 1988; 51:914-9.
33. Deutch AY, Elsworth JD, Roth RH, Goldstein M. 3-Acetylpyridine results in degeneration of the extrapyramidal and cerebellar motor systems: loss of dorsolateral striatal dopamine innervation. Brain Res 1990;527: 96-102.
34. Amalric M, Kool DF. Depletion of dopamine in the caudate nucleus but not in the nucleus accumbens impairs reaction-time performance in rats. J Neurosci 1987;7: 2129-34.
35. Taghzouti K, Le Noal M, Simon H. Suppression of noradrenergic innervation compensates for behavioral deficits induced by lesion of dopaminergic terminals in the lateral septum. Brain Res 1991;552:124-8.
36. Robbins TW, Everett BJ. Arousal systems and attention. In: Gazzaniga MS, ed. The cognitive neurosciences. Cambridge, Massachusetts: MIT Press, 1995:703-19.
37. Sawaguchi T. Catecholamine sensitivities of neurons related to a visual reaction time task in the monkey pre-frontal cortex. J Neurophysiol 1987;58:1100-22.
38. Kish SJ, Robitaille Y, El-Awar M, Clark B, Schut L, Ball JM, et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 1992;42:1573-7.
39. Heilman KM. Attentional asymmetries. In: Davidson RJ, Hugdahl K, eds. Brain asymmetry. Cambridge, Massachusetts: MIT Press, 1994;9:217-23.
40. Tucker DM, Williamson PA. Asymmetric neural control in human self-regulation. Psychol Rev 1984;91:185-215.
41. Wittling W. Brain asymmetry in the control of autonomic - physiologic activity. In: Davidson RJ, Hugdahl K, eds. Brain asymmetry. Cambridge, Massachusetts: MIT Press, 1994;12:305-10.
42. Louillot A, Le Moal M. Lateralized interdependence between limbicocortical and ventrostriatal dopaminergic transmission. Neuroscience 1994;59:495-500.
43. Oke A, Lewis R, Adams RN. Hemispheric asymmetry of norepinephrine distribution in rat thalamus. Brain Res 1980;188:269-72.
44. Von Voigtlander P, Moore K. Dopamine: release from the brain in vivo by amantadine. Science 1970;174:408-10.
45. Goetz CG, Tanner CM, Klawans HL. The pharmacology of olivopontocerebellar atrophy. Adv Neurol 1984;41: 143-8.
46. Oertel WH. Neurotransmitters in the cerebellum. Scientific aspects and clinical relevance. In: Harding AE, Deufel T, eds. Advances in neurology. New York: Raven Press 1993; 61:33-75.
47. Cox JA, Lysko PG, Henneberry RC. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: role of the voltage dependent magnesium block. Brain Res 1989;499:266-72.
48. Henneberry RC, Novelli A, Cox JA, Lysko PG. Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons. Ann NY Acad Sci 1989; 558:225-33.
49. Boje KM, Wong G, Skolnik P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell culture. Brain Res 1993;603:207-14.
50. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989;166:591-2.
51. 3H) MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989;166:589-90.
52. Erdo SL, Schaefer M. Memantine is highly potent in protecting cortical cultures against excitotoxic death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 1991;198:215-7.
53. Lalonde R, Joyal CC, Guastavino J-M, Côté C, Botez MI. Amantadine and ketamine-induced improvement of motor coordination in lurcher mutant mice. Restor Neurol Neurosci 1993;5:367-70.
54. Filla A, De Michele G, Orefice G, Campanella G. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Can J Neurol Sci 1993;20:52-5.